New Pfizer partnership with Rexall Drugstore will help patients to stay on treatment
Patients who fill three or more chronic medications on a regular basis are eligible for the service and will enroll directly with their Rexall pharmacist. Following enrollment, in consultation with their pharmacist, a patient's medications will be synched so that they are refilled on a date that works best for them.
Pfizer Canada has partnered with Rexall in a new service called OneStopMeds to improve medication adherence and health outcomes for patients taking multiple chronic medications.
Low adherence to treatment is a significant issue in the Canadian healthcare system:
In fact, 6 months after being prescribed a specific treatment, 50% of patients do not adhere to it and this statistic has remained unchanged for the last 30 years. This issue is important since patients do not benefit from appropriate health outcomes and a partial course of treatment leads to inefficient use of already scarce healthcare resources.
The OneStopMeds partnership between Rexall and Pfizer aims to improve these numbers. Patients who fill three or more chronic medications on a regular basis are eligible for the service and will enroll directly with their Rexall pharmacist. Following enrollment, in consultation with their pharmacist, a patient's medications will be synched so that they are refilled on a date that works best for them. OneStopMeds reduces the number of trips to the pharmacy, ensures the patient has all of their medications and drives the pharmacist to engage and speak with their patients about their overall health and the medications they are taking.
''Pfizer is committed to working collaboratively with our pharmacy partners to demonstrate the value and role pharmacists play in the healthcare system'' said Gerry Stefanatos, General Manager, Global Established Products, Pfizer Canada. ''Partnerships such as OneStopMeds will improve medication adherence and ultimately patient care'' he added.
"Rexall and our pharmacists are leading the way when it comes to delivering patient focused services and the launch of OneStopMeds is another important step towards improving the health and wellness of Canadians," said Jürgen Schreiber, CEO of Rexall Health.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.